Sermorelin injections, dissolving tablets and nasal spray

The forms sold online

Most providers in our comparison sell sermorelin as an injection under the skin. Some also sell a form taken by mouth: a tablet that dissolves on the tongue, or a lozenge held under it. The table shows what each provider sells and at what price, as read on its own pages.

What the FDA approved, and in what form

The only sermorelin products the FDA has approved were injections sold under the name Geref. One was approved in 1990 to test whether the pituitary gland can release growth hormone. The other was approved in 1997 for children with growth failure caused by idiopathic growth hormone deficiency.¹

The manufacturer discontinued both in 2008, and the FDA withdrew their approval in 2009. The agency later determined that they had not been withdrawn for reasons of safety or effectiveness.¹

What online providers ship today is compounded sermorelin, whatever the form. The FDA states that compounded drugs are not FDA-approved, which means the agency does not verify their safety, effectiveness or quality before they are marketed.²

What studies show about the nasal route

In a 1985 study in healthy men, growth-hormone-releasing hormone released growth hormone whether it was given into a vein, under the skin or into the nose, but much higher doses were needed by the last two routes. After the same dose, the peak blood level of the hormone was about 60 times lower under the skin and about 500 times lower through the nose than into a vein.³

A 1986 study of a 29-amino-acid analog found that an intranasal dose thirty times the intravenous dose produced about one fifth of the growth hormone release.⁴

A six-month pilot study gave the 29-amino-acid peptide as a nasal spray to eight children with growth hormone deficiency. Absorption and effect fell over time, antibodies appeared in three children, and most reported sneezing, a runny nose and mild burning. The authors concluded that the nasal form was not suitable for children as it stood.⁵

The first study used the full 40-amino-acid hormone and the second a modified analog, so neither tested the product sold today.

Tablets and lozenges: no published study found

On November 12, 2026 we searched PubMed for studies whose title or abstract mentions sermorelin together with oral, sublingual, buccal, lozenge, troche or tablet. The search returned no result.⁶

We therefore cannot point to published evidence that a dissolving tablet or a lozenge delivers sermorelin the way an injection does. A search of titles and abstracts can miss studies, so read this as none found, not none exists.

Questions to ask the prescriber

• Why this form for me, and what evidence supports it?
• How was the dose chosen, and how does it compare with the injected dose?
• How will you check whether it is working?
• Which pharmacy prepares it?
• What do I pay if I stop after the first month?

Sources

1. FDA, Federal Register, March 4, 2013: Determination that Geref (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectiveness. Read November 12, 2026.
2. FDA, Compounding and the FDA: Questions and Answers. Read November 12, 2026.
3. Evans WS, et al. Effects of intravenous, subcutaneous, and intranasal administration of growth hormone (GH)-releasing hormone-40 on serum GH concentrations in normal men. J Clin Endocrinol Metab. 1985;61(5):846-50. Read November 12, 2026.
4. Vance ML, et al. The effect of intravenous, subcutaneous, and intranasal GH-RH analog, [Nle27]GHRH(1-29)-NH2, on growth hormone secretion in normal men. Clin Pharmacol Ther. 1986;40(6):627-33. Read November 12, 2026.
5. Hümmelink R, et al. Intranasal administration of growth hormone-releasing hormone(1-29)-NH2 in children with growth hormone deficiency. Acta Paediatr Suppl. 1993;388:23-6. Read November 12, 2026.
6. PubMed search of titles and abstracts: sermorelin with oral, orally, sublingual, troche, lozenge, buccal or tablet (no result). Read November 12, 2026.